Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader

Area of Science:

• Oncology
• Endocrinology
• Rare Cancers

Background:

• Myoepithelial tumors are rare malignancies primarily affecting salivary glands and extremities.
• No established treatment guidelines exist for myoepithelial tumors due to their infrequency.

Observation:

• A male patient presented with metastatic myoepithelial tumor.
• Molecular testing guided the treatment decision.

Findings:

• The patient received bicalutamide, an androgen-receptor (AR) antagonist, resulting in successful treatment.
• This is the first reported case demonstrating the efficacy of anti-androgens in managing myoepithelial tumors.
• The patient later developed metastatic prostate cancer six years into treatment.

Implications:

• Anti-androgen therapy shows promise for treating metastatic myoepithelial tumors.
• Close monitoring for prostate cancer is crucial in patients receiving AR-targeted therapy for myoepithelial tumors.
• Prostate-specific antigen (PSA) levels may be altered by bicalutamide, necessitating careful interpretation during cancer screening.